Lonza Biologics Inc.

Lonza to expand bioconjugation capabilities in Visp, adding 2,000m² with two 1,200L suites for launch and commercial supply, expected to create 200 jobs by 2028. This doubles multipurpose capacity, supporting complex ADC and bioconjugate manufacturing, and follows sustainability design standards.

Methods for keloid spheroid formation, viability, composition, and propagation assays are detailed, involving fibroblasts and endothelial cells. Fibroblasts from commercial lines and keloid patients, and HUVECs, were cultured and mixed to form spheroids. Viability, composition, and propagation of spheroids were assessed using fluorescent staining and microscopy. Gene expression analysis by RT-PCR and drug assays with triamcinolone, fluorouracil, and bleomycin were conducted. Statistical analysis was performed using Prism 9.3.1, with significance set at p < 0.05.

The 'Biotechnology for the Non-Biotechnologist Training Course' by ResearchAndMarkets.com offers a 5-day intensive overview of biotech product development, manufacturing, and regulatory environments, focusing on biosimilars, advanced therapies, and patents.

The global induced pluripotent stem cells (iPSCs) market, valued at USD 1.88 billion in 2023, is projected to grow to USD 4.48 billion by 2032, driven by advancements in regenerative and personalized medicine, drug discovery, and increased investments in stem cell research. Key market participants focus on improving iPSC generation methods, while challenges include high production costs, ethical issues, and regulatory complexities. North America leads the market, with Asia-Pacific showing rapid growth.

Challenges in scaling cell and gene therapy manufacturing mirror those of antibodies, with automation and digitization key to reducing costs. Companies like Cellares and Cellular Origins aim to automate processes, while Lonza and BioCentriq focus on cost-effective production. Bit.bio targets industrial-scale production of specific human cell types, highlighting the complexity and potential of the field.

The Pharmaceutical Contract Manufacturing Market is projected to exceed $155 billion in 2024, driven by high in-house drug development costs and varying regulatory requirements. CDMOs like Thermo Fisher Scientific and Samsung Biologics are expanding services to meet demand, offering end-to-end solutions from development to commercial-scale manufacturing. The market report provides revenue forecasts to 2034, regional and national market analyses, and profiles of leading companies.

Synaffix and BigHat Biosciences collaborate to develop next-gen ADCs, combining Synaffix's ADC platform with BigHat's AI/ML-powered Milliner. The partnership aims to create safer, more effective treatments for difficult-to-treat cancers, leveraging Synaffix's conjugation and linker-payload technologies. ADCs, a growing $11.3 billion market, are seen as more effective and safer than conventional treatments, targeting cancers like blood, breast, urothelial, and bladder.

Vertex Pharmaceuticals reported strong Q3 2024 results, with $2.77 billion in revenue, a 12% increase from Q3 2023. The company highlighted continued commercial execution in cystic fibrosis (CF) and the early launch of CASGEVY, a transformative one-time therapy for sickle cell disease and beta-thalassemia. Vertex is preparing for potential near-term approvals of vanzacaftor triple in CF and suzetrigine in moderate to severe acute pain. The company also advanced three new programs into Phase 3 clinical trials and is investing in additional manufacturing capacity for CASGEVY. Vertex raised its full-year product revenue guidance to $10.8 billion to $10.9 billion.

Pyrogen Testing Market size is projected to reach USD 2.8 billion by 2032, driven by the expanding pharmaceutical and biotechnology industries. The rise in drug development and biologics manufacturing globally increases demand for pyrogen testing to ensure product safety. Advances in testing technologies, such as recombinant factor C (rFC) assays and in vitro methods, offer efficient, ethical, and cost-effective alternatives to traditional animal-based tests. The in vitro pyrogen test segment is expected to grow significantly due to its ethical and cost-effective advantages. Medical device companies also show strong demand for pyrogen testing to ensure device safety. Asia Pacific is anticipated to be a lucrative market, driven by expanding pharmaceutical industries in countries like China and India.